Alpha TeknovaTKNO
TKNO
About: Alpha Teknova Inc provides critical reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its product offerings include pre-poured media plates for cell growth and cloning, liquid cell culture media and supplements for cellular expansion, and molecular biology reagents for sample manipulation, resuspension, and purification. It derives maximum revenue from United States.
Employees: 211
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
207% more capital invested
Capital invested by funds: $8.09M [Q2] → $24.9M (+$16.8M) [Q3]
57% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 7
22% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 9
14% more funds holding
Funds holding: 28 [Q2] → 32 (+4) [Q3]
4.81% less ownership
Funds ownership: 14.46% [Q2] → 9.64% (-4.81%) [Q3]
Research analyst outlook
We haven’t received any recent analyst ratings for TKNO.
Financial journalist opinion
Neutral
Seeking Alpha
1 month ago
Alpha Teknova, Inc. (TKNO) Q3 2024 Earnings Call Transcript
Alpha Teknova, Inc. (NASDAQ:TKNO ) Q3 2024 Earnings Conference Call November 7, 2024 5:30 PM ET Company Participants Jennifer Henry – Senior Vice President-Marketing Stephen Gunstream – President and Chief Executive Officer Matt Lowell – Chief Financial Officer Conference Call Participants Chad Wiatrowski – TD Cowen Lucas Baranowski – KeyBanc Capital Markets Vidyun Bais – BTIG Jacob Johnson – Stephens Matt Larew – William Blair Operator Hello, and welcome to Alpha Teknova Third Quarter 2024 Financial Results. At this time all participants are in a listen-only mode.
Neutral
GlobeNewsWire
1 month ago
Teknova Reports Third Quarter 2024 Financial Results
Third quarter 2024 total revenue was $9.6 million, up 17% over the same quarter prior year Company lowers 2024 total free cash outflow outlook to less than $16 million Company reaffirms 2024 revenue guidance of $35-38 million
Neutral
GlobeNewsWire
1 month ago
Teknova to Report Third Quarter 2024 Financial Results on November 7, 2024
HOLLISTER, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the third quarter ended September 30, 2024, on Thursday, November 7, 2024, following the close of market.
Positive
Zacks Investment Research
1 month ago
What Makes Alpha Teknova (TKNO) a Strong Momentum Stock: Buy Now?
Does Alpha Teknova (TKNO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Neutral
Seeking Alpha
4 months ago
Alpha Teknova, Inc. (TKNO) Q2 2024 Earnings Call Transcript
Alpha Teknova, Inc. (NASDAQ:TKNO ) Q2 2024 Earnings Conference Call August 13, 2024 5:00 PM ET Company Participants Jennifer Henry - SVP, Marketing Stephen Gunstream - President & CEO Matt Lowell - CFO Conference Call Participants Mark Massaro - BTIG Jacob Johnson - Stephens Steven Mah - TD Cowen Paul Knight - KeyBanc Matt Larew - William Blair Operator Good day and thank you for standing by. Welcome to the Teknova's Second Quarter 2024 Financial Results.
Neutral
GlobeNewsWire
4 months ago
Teknova Reports Second Quarter 2024 Financial Results
Second quarter 2024 total revenue was $9.6 million, up 3% sequentially Raised $15.4 million of equity capital in July 2024 Launched two new offerings: Express-TekSM Production and RUO+ manufacturing grade Company reaffirms 2024 revenue guidance of $35-38 million
Neutral
GlobeNewsWire
4 months ago
Teknova to Report Second Quarter 2024 Financial Results on August 13, 2024
HOLLISTER, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the second quarter ended June 30, 2024, on Tuesday, August 13, 2024, following the close of market.
Negative
24/7 Wall Street
5 months ago
Recent Insider Buying Is Focused on These 5 Stocks
24/7 Insights With the new quarter begun and second-quarter earnings reports starting to come in, insider buying has slowed to a trickle.
Neutral
GlobeNewsWire
5 months ago
Teknova Announces Closing of $15.4 Million Private Placement
HOLLISTER, Calif., July 12, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced the closing of its previously announced private placement for the issuance and sale of an aggregate of 12,385,883 shares of its common stock at a purchase price of $1.24 per share. The private placement was priced based on the Nasdaq Official Closing Price of Teknova's common stock on July 11, 2024.
Neutral
GlobeNewsWire
5 months ago
Teknova Announces $15.4 Million Private Placement
HOLLISTER, Calif., July 11, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate 12,385,883 of its shares of common stock in a private placement at a purchase price of $1.24 per share. The private placement was priced based on the Nasdaq Official Closing Price of Teknova's common stock on July 11, 2024.
Charts implemented using Lightweight Charts™